Growing Diabetes Drug Innovation Fails to Address Insulin Access Gaps, Report Finds

The article focuses on the 2026 Access to Medicine Index's findings on pharmaceutical companies' investment in diabetes care products. 

Specifically, it highlights the report's finding that there are 25 active diabetes research and development projects across six pharmaceutical companies in scope of the report, with innovation largely concentrated on GLP-1 medicines. However, essential insulin is still not reliably available in many low- and middle-income countries. 

It points out that pharmaceutical companies Lilly, Novo Nordisk and Sanofi have undertaken initiatives aimed at expanding insulin access, but significant gaps remain, particularly in lower-income countries.